This is a prospective, randomized, parallel-group, blinded-endpoint, single-center clinical study aimed at investigating the preventive effects of PCSK9 inhibitors on END in patients with AIS and a history of CHD within 24 h of symptom onset. This evidence concerns the gene PCSK9 and androgen insensitivity syndrome.